Your browser is no longer supported. Please, upgrade your browser.
GWPH [NASD]
GW Pharmaceuticals plc
Index- P/E- EPS (ttm)-1.73 Insider Own0.64% Shs Outstand31.36M Perf Week2.81%
Market Cap4.49B Forward P/E337.38 EPS next Y0.42 Insider Trans-91.59% Shs Float30.87M Perf Month16.70%
Income-53.90M PEG- EPS next Q-0.82 Inst Own84.50% Short Float9.58% Perf Quarter46.25%
Sales488.10M P/S9.19 EPS this Y97.60% Inst Trans0.16% Short Ratio7.18 Perf Half Y9.84%
Book/sh23.42 P/B6.05 EPS next Y122.70% ROA-6.10% Target Price182.50 Perf Year22.26%
Cash/sh15.17 P/C9.34 EPS next 5Y- ROE-7.50% 52W Range67.98 - 144.00 Perf YTD22.78%
Dividend- P/FCF- EPS past 5Y19.00% ROI-15.90% 52W High-1.60% Beta2.05
Dividend %- Quick Ratio4.30 Sales past 5Y59.60% Gross Margin92.90% 52W Low108.44% ATR5.81
Employees901 Current Ratio5.10 Sales Q/Q50.70% Oper. Margin-10.00% RSI (14)71.37 Volatility4.89% 4.48%
OptionableYes Debt/Eq0.02 EPS Q/Q12.40% Profit Margin-11.00% Rel Volume0.68 Prev Close138.42
ShortableYes LT Debt/Eq0.02 EarningsNov 03 BMO Payout- Avg Volume411.89K Price141.70
Recom1.80 SMA2013.16% SMA5013.58% SMA20023.07% Volume278,472 Change2.37%
Aug-25-20Initiated Raymond James Mkt Perform
Aug-07-20Reiterated Needham Buy $190 → $180
Jul-15-20Downgrade Stifel Buy → Hold $150 → $140
Jun-30-20Reiterated Evercore ISI Outperform $250 → $275
Jun-01-20Resumed Oppenheimer Outperform $173 → $166
Apr-08-20Initiated Northland Capital Outperform $128
Mar-06-20Initiated Citigroup Buy $192
Oct-30-19Initiated H.C. Wainwright Buy $170
Oct-21-19Initiated Needham Buy $200
May-07-19Upgrade Oppenheimer Perform → Outperform
May-07-19Reiterated Guggenheim Buy $186 → $222
May-07-19Reiterated Cantor Fitzgerald Overweight $196 → $229
Mar-18-19Reiterated Cantor Fitzgerald Overweight $193 → $196
Jan-02-19Initiated JP Morgan Overweight $134
Nov-05-18Resumed Piper Jaffray Overweight
Sep-28-18Reiterated BofA/Merrill Buy $181 → $197
Sep-07-18Resumed Morgan Stanley Overweight
Aug-15-18Initiated Stifel Buy $181
Aug-08-18Reiterated Cantor Fitzgerald Overweight $235 → $211
Apr-19-18Reiterated Cantor Fitzgerald Overweight $192 → $205
Jan-16-21 09:25AM  
Jan-13-21 10:37AM  
Jan-12-21 06:36AM  
Jan-11-21 07:21AM  
07:00AM  
06:08AM  
Jan-09-21 03:23AM  
Jan-05-21 12:24PM  
07:30AM  
Dec-30-20 08:43AM  
Dec-21-20 11:30AM  
Dec-19-20 06:36AM  
Dec-16-20 05:33PM  
Dec-07-20 07:00AM  
Dec-04-20 12:54PM  
Dec-03-20 01:39PM  
Dec-02-20 06:08PM  
Dec-01-20 12:00PM  
08:30AM  
Nov-30-20 07:32AM  
Nov-25-20 12:52AM  
Nov-17-20 09:40AM  
Nov-13-20 01:31PM  
08:30AM  
Nov-09-20 07:30AM  
Nov-04-20 04:23PM  
12:53PM  
09:26AM  
02:36AM  
Nov-03-20 07:00PM  
01:58PM  
01:01PM  
01:01PM  
11:03AM  
07:47AM  
07:30AM  
07:30AM  
07:15AM  
06:30AM  
Nov-02-20 10:47AM  
10:43AM  
10:18AM  
08:50AM  
08:50AM  
Oct-30-20 11:15AM  
Oct-29-20 11:34AM  
Oct-27-20 10:36AM  
Oct-26-20 08:00AM  
07:56AM  
07:54AM  
Oct-22-20 10:34AM  
Oct-21-20 08:00AM  
Oct-19-20 10:39AM  
Oct-16-20 11:02AM  
Oct-15-20 02:45PM  
Oct-12-20 09:50AM  
Oct-10-20 10:45AM  
Sep-23-20 08:05AM  
08:00AM  
03:54AM  
Sep-15-20 07:52AM  
Sep-10-20 04:00PM  
04:00PM  
07:08AM  
07:00AM  
Sep-03-20 06:30AM  
Sep-02-20 01:24PM  
Sep-01-20 07:00AM  
Aug-29-20 06:41AM  
Aug-26-20 12:38PM  
Aug-24-20 07:21AM  
Aug-16-20 10:47AM  
Aug-07-20 11:24AM  
07:34AM  
Aug-06-20 04:44PM  
04:00PM  
Aug-03-20 03:45PM  
03:36PM  
02:05PM  
01:01PM  
07:00AM  
01:29AM  
Aug-02-20 09:34AM  
Jul-30-20 11:53AM  
Jul-26-20 09:54AM  
08:10AM  
Jul-25-20 06:56AM  
Jul-23-20 07:00AM  
Jul-21-20 03:09PM  
Jul-17-20 04:21PM  
12:27PM  
09:05AM  
Jul-15-20 06:51PM  
08:22AM  
Jul-14-20 08:08AM  
Jul-13-20 07:21AM  
Jul-12-20 09:34AM  
08:24AM  
Jul-11-20 07:48AM  
Jul-09-20 06:49AM  
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, Dravet syndrome, and Lennox-Gastaut syndrome, as well as in phase III clinical trials for the treatment of tuberous sclerosis complex. The company also develops and markets Sativex for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates for the treatment of for schizophrenia, autism spectrum disorder, and neonatal hypoxic ischemic encephalopathy. It primarily operates in Europe, the United Kingdom, the United States, and internationally. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
George Adam D.SecretaryJan 19Option Exercise9.619,60092,25619,600Jan 20 08:00 PM
George Adam D.SecretaryJan 19Sale11.689,600112,12810,000Jan 20 08:00 PM
Knappertz VolkerChief Medical OfficerJan 19Sale11.676,00070,02017,940Jan 20 08:00 PM
George Adam D.SecretaryJan 15Option Exercise10.0679,860803,68389,860Jan 20 08:00 PM
George Adam D.SecretaryJan 15Sale11.7379,860936,75410,000Jan 20 08:00 PM
George Adam D.SecretaryJan 13Option Exercise0.37675,744252,710685,744Jan 15 08:00 PM
George Adam D.SecretaryJan 13Sale11.03675,7447,454,00910,000Jan 15 08:00 PM
Brown CabotDirectorJan 04Option Exercise0.003,576510,776Jan 06 09:31 PM
Secor AliciaDirectorJan 04Option Exercise0.003,576510,140Jan 06 09:31 PM
MACKEY CATHERINE JDirectorJan 04Option Exercise0.003,576510,092Jan 06 09:31 PM
GUY GEOFFREY W DRExecutive ChairmanDec 08Sale10.74240,0002,577,2944,781,521Dec 14 09:30 PM
GUY GEOFFREY W DRExecutive ChairmanDec 07Sale11.00480,0005,282,3645,021,521Dec 14 09:30 PM
Snyder Douglas B.Chief Legal OfficerDec 07Sale11.0126,904296,2900Dec 09 08:00 PM
Tovey Christopher J.Chief Operating OfficerDec 01Option Exercise0.0028,5603731,056Dec 02 09:00 PM
Tovey Christopher J.Chief Operating OfficerDec 01Sale11.7628,560335,7472,496Dec 02 09:00 PM
Tovey Christopher J.Chief Operating OfficerNov 30Option Exercise0.0093,46812295,964Dec 02 09:00 PM
Tovey Christopher J.Chief Operating OfficerNov 30Sale11.6793,4681,090,7722,496Dec 02 09:00 PM
Knappertz VolkerChief Medical OfficerNov 24Sale10.5012,000126,00023,940Nov 25 08:00 PM
Gover Justin D.Chief Executive OfficerNov 17Option Exercise0.0042,70856498,761Nov 17 09:00 PM
Gover Justin D.Chief Executive OfficerNov 17Sale10.0342,708428,361456,053Nov 17 09:00 PM
Gover Justin D.Chief Executive OfficerNov 16Option Exercise0.0022,80030478,853Nov 17 09:00 PM
Gover Justin D.Chief Executive OfficerNov 16Sale10.0222,800228,456456,053Nov 17 09:00 PM
Gover Justin D.Chief Executive OfficerNov 13Option Exercise0.0042,98456499,037Nov 17 09:00 PM
Gover Justin D.Chief Executive OfficerNov 13Sale10.0142,984430,270456,053Nov 17 09:00 PM
Gover Justin D.Chief Executive OfficerNov 12Option Exercise0.0064,30884520,361Nov 12 09:00 PM
Gover Justin D.Chief Executive OfficerNov 12Sale10.0164,308643,723456,053Nov 12 09:00 PM
Knappertz VolkerChief Medical OfficerNov 11Sale10.006,00060,00035,940Nov 13 08:00 PM
Gover Justin D.Chief Executive OfficerNov 09Option Exercise0.007,2009463,253Nov 12 09:00 PM
Gover Justin D.Chief Executive OfficerNov 09Sale10.007,20072,000456,053Nov 12 09:00 PM
Knappertz VolkerChief Medical OfficerNov 04Sale9.176,00055,02041,940Nov 05 08:00 PM
GUY GEOFFREY W DRExecutive ChairmanNov 03Option Exercise0.00307,1523995,808,673Nov 05 09:08 PM
GUY GEOFFREY W DRExecutive ChairmanNov 03Sale8.48307,1522,605,9905,501,521Nov 05 09:08 PM
Snyder Douglas B.Chief Legal OfficerSep 30Sale8.1314,400117,07226,904Oct 02 04:40 PM
Snyder Douglas B.Chief Legal OfficerAug 11Sale9.4024,000225,60041,304Aug 12 08:06 PM
Snyder Douglas B.Chief Legal OfficerAug 10Option Exercise0.00131,544171122,364Aug 12 08:06 PM
Knappertz VolkerChief Medical OfficerAug 04Sale11.116,00066,66047,940Aug 06 08:01 PM
Knappertz VolkerChief Medical OfficerJul 20Sale11.426,00068,52053,940Jul 22 08:00 PM
Snyder Douglas B.Chief Legal OfficerJul 06Sale10.509,804102,9420Jul 08 08:00 PM
Knappertz VolkerChief Medical OfficerJun 17Sale10.3518,000186,30059,940Jun 19 08:02 PM
Gover Justin D.Chief Executive OfficerJun 15Option Exercise0.004,1645458,129Jun 17 08:00 PM
GUY GEOFFREY W DRExecutive ChairmanMay 29Sale10.25720,0007,376,4005,501,521Jun 02 08:00 PM
Cline Darren SU.S. Chief Commercial OfficerMay 28Option Exercise0.007,35697,356May 29 08:00 PM
Knappertz VolkerChief Medical OfficerMay 18Option Exercise0.00133,620160139,092May 20 08:02 PM
Giacobello Scott M.Chief Financial OfficerMay 18Option Exercise0.00116,604140140,742May 20 08:01 PM
Giacobello Scott M.Chief Financial OfficerMar 13Buy6.807,20048,96088,224Mar 17 06:07 PM
GUY GEOFFREY W DRExecutive ChairmanMar 13Sale6.63600,0003,978,0006,221,521Mar 17 06:05 PM
Gover Justin D.Chief Executive OfficerMar 02Option Exercise0.0047,84462599,369Mar 04 06:01 PM
Snyder Douglas B.Chief Legal OfficerMar 02Sale8.322,56821,36667,296Mar 04 06:03 PM
MACKEY CATHERINE JDirectorMar 02Sale8.351,35611,32316,392Mar 04 06:04 PM
Brown CabotDirectorMar 02Sale8.243,14425,90717,088Mar 04 06:03 PM
Gover Justin D.Chief Executive OfficerMar 02Sale8.3332,856273,789566,513Mar 04 06:01 PM
Secor AliciaDirectorMar 02Sale8.341,29610,80916,440Mar 04 06:02 PM
Giacobello Scott M.Chief Financial OfficerMar 02Sale8.342,22018,51581,024Mar 04 06:00 PM
Knappertz VolkerChief Medical OfficerMar 02Sale8.323,42028,45479,392Mar 04 06:01 PM
Snyder Douglas B.Chief Legal OfficerFeb 26Sale9.173,87635,55069,864Feb 28 06:06 PM
Gover Justin D.Chief Executive OfficerFeb 26Sale9.0512,000108,558551,525Feb 28 06:02 PM
Knappertz VolkerChief Medical OfficerFeb 26Sale9.183,01227,63682,812Feb 28 06:02 PM
Giacobello Scott M.Chief Financial OfficerFeb 26Sale9.173,85235,32383,244Feb 28 06:01 PM
Gover Justin D.Chief Executive OfficerFeb 03Option Exercise0.00202,224263765,749Feb 05 05:00 PM
Gover Justin D.Chief Executive OfficerFeb 03Sale9.62202,2241,944,678563,525Feb 05 05:00 PM